IMNN Stock Overview

A clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. More details

IMNN fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 22% per year for the next 3 years

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Imunon, Inc. Competitors

Unity Biotechnology

NasdaqGS:UBX

US$16.9m

iBio

NYSEAM:IBIO

US$22.1m

Turnstone Biologics

NasdaqGM:TSBX

US$10.5m

Finch Therapeutics Group

OTCPK:FNCH

US$17.7m

Price History & Performance

Summary of share price highs, lows and changes for Imunon
Historical stock prices
Current Share Price	US$0.81
52 Week High	US$3.65
52 Week Low	US$0.48
Beta	2.09
1 Month Change	0.37%
3 Month Change	-19.31%
1 Year Change	12.72%
3 Year Change	-90.36%
5 Year Change	-96.82%
Change since IPO	-100.00%

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Shareholder Returns

	IMNN	US Biotechs	US Market
7D	-6.0%	-3.3%	-2.2%
1Y	12.7%	-1.9%	23.9%

Return vs Industry: IMNN exceeded the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: IMNN underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement	8.7%
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IMNN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IMNN's weekly volatility has decreased from 31% to 9% over the past year.

About the Company

Founded	Employees	CEO	Website
1982	33	Stacy Lindborg	imunon.com

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.

Imunon, Inc. Fundamentals Summary

How do Imunon's earnings and revenue compare to its market cap?
IMNN fundamental statistics
Market cap	US$11.82m
Earnings (TTM)	-US$19.45m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Is IMNN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMNN income statement (TTM)
Revenue	US$0
Cost of Revenue	US$1.67m
Gross Profit	-US$1.67m
Other Expenses	US$17.78m
Earnings	-US$19.45m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.34
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did IMNN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 22:28
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Imunon, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Raymond Deacon	Brean Capital
Kumaraguru Raja	Brookline Capital Markets

IMNN Stock Overview

Risk Analysis

Imunon, Inc. Competitors

NasdaqGS:UBX

US$16.9m

NYSEAM:IBIO

US$22.1m

NasdaqGM:TSBX

US$10.5m

OTCPK:FNCH

US$17.7m

Price History & Performance

Recent News & Updates

IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001

Imunon, Inc. Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

New major risk - Market cap size

New major risk - Financial position

Recent updates

IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001

Imunon, Inc. Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

New major risk - Market cap size

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

Price target decreased by 17% to US$10.00

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind